Trump Slams FDA Regulations In Joint Session Of Congress
Executive Summary
US president hit on his sentiments of faster drug approval times and deregulation, signaling FDA could be in for period of sustained criticism.
You may also be interested in...
Trump Praises FDA, But May Leave Firms Queasy With Pricing, Right-To-Try Comments
State of the Union address touts FDA's record number of approvals, but also endorses right to try proposals and renews president's call for lower drug prices.
FDA Soliciting Broad Range Of Comments From Industry On Regulatory Reform
FDA is addressing regulatory reform as part of President Trump's "two-for-one" executive order, and seeks industry comments to supplement the effort.
Can The FDA Climate Be Too Good?
US FDA’s decision to accept Amicus’ migalastat NDA without a new study is the latest sign of the positive climate for rare disease drugs at FDA. But will it be remembered as a turning point?